CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $207.5 million in its fourth quarter.
The Cambridge, Massachusetts-based company said it had a loss of $1.68 per share.
The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $2.13 per share.
The RNA interference drug developer posted revenue of $335 million in the period, which also beat Street forecasts. Ten analysts surveyed by Zacks expected $306.3 million.
For the year, the company reported that its loss widened to $1.13 billion, or $9.30 per share. Revenue was reported as $1.04 billion.
Alnylam shares have dropped 15% since the beginning of the year. The stock has risen 37% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a ALNY">Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY